The iCMLf is hosting conversations on CML and COVID-19 with renowed experts in CML that address key questions on how to manage patients with CML during the COVID-19 pandemic. You can view recordings of the conversations here. The content of the presentations express the individual opinions of the respective experts. 
 
|   
 Professor Jorge Cortes Director, Georgia Cancer Center  Augusta (USA) 
 | 
  | 
  CML in the era of COVID-19  incl. Q&A session 
  
Watch the webinar to hear Professor Cortes' experience and perspectives on topics like; 
- COVID-19 in cancer patients in China / New York 
  
- Outcomes in patients with cancer and COVID-19
 
- COVID-19 mortality in patients with cancer
 
- COVID-19 in patients with hematological malignancies
 
- COVID-19 in patients with chronic myeloid leukemia
 
- Treating leukemia in the time of COVID-19
 
- TKI's and COVID-19
 
- Vaccination in patients with CML
 
- CML and COVID-19 recommendations
 
 
 | 
|   
 Professor Gianantonio Rosti St Orsola University Hospital Bologna (Italy) 
 | 
  | 
   
  
 Management recommendations for patients with CML during the pandemic incl. Q&A Session 
Watch the webinar to hear Professor Rosti's experience and perspectives on topics like; 
- Newly diagnosed patients
- How to begin therapy?
 
- What therapies and why?
 
- Any concerns about delaying therapy?
 
- Recommendations for patients
 
 
 
- Patients on TKI therapy
- Should therapy be switched or stopped pre-emptively?
 
- How should patients with CML be monitored?
 
 
 
- Treatment-free-remission, suggestions
- For those patients considering TFR
 
- For those patients already in TFR
 
 
  
 
 
  
 | 
|   
 Dr Delphine Réa Hôpital Saint-Louis  Paris (France) 
 | 
  | 
   
  
  
  
Management of patients with CML and COVID-19 incl. Q&A Session 
Watch the webinar to hear Dr Rea's experience and perspectives on topics like; 
- SARS-CoV-2 infection and COVID-19: symptoms and diagnostic tools
 
- Classication of COVID-19 according to WHO
 
- CML and COVID-19: personal experience
 
- CML and asymptomatic SARS CoV-2 infection
 
- CML and mild/moderate/severe/critical (WHO) COVID-19
 
- Adapting TKI treatment strategy according to COVID-19 severity: personal suggestions
 
- Drugs used or tested against COVID-19: potential interactions with CML TKI's
 
- Prevention of COVID-19 in CML patients
 
 
  
  
  
  
  
 | 
|  
 Professor Hemant Malhotra Mahatma Gandhi Medical College Hospital, Jaipur (India) 
Dr Katia Pagnano University of Campinas,   Sao Paulo   (Brazil) 
                                                    
 
  
 | 
  | 
   
 What do we know about COVID-19 and CML so far from real-world? Perspectives from India and Brazil incl. Q&A Session 
Watch the webinar to hear  Prof. Malhotra's and Dr Pagnano's experience and local perspectives on topics like; 
- Global data on CML and COVID-19 from the iCMLf/ASH
 
- CML and COVID-19 cases in India and Brazil
 
- CML and COVID-19: local experiences, strategy and specific challenges
 
- Changes in management of patients with CML during the pandemic
 
- Prevention of Coronavirus infection at local centres in India/Brazil
 
 
  
  
  
 |